U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H20ClF2N3O3S
Molecular Weight 455.906
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ABT-639

SMILES

[H][C@]12CCCN1CCN(C2)C(=O)C3=CC(=C(F)C=C3Cl)S(=O)(=O)NC4=CC=CC=C4F

InChI

InChIKey=AGPIHNZOZNKRGT-CYBMUJFWSA-N
InChI=1S/C20H20ClF2N3O3S/c21-15-11-17(23)19(30(28,29)24-18-6-2-1-5-16(18)22)10-14(15)20(27)26-9-8-25-7-3-4-13(25)12-26/h1-2,5-6,10-11,13,24H,3-4,7-9,12H2/t13-/m1/s1

HIDE SMILES / InChI

Molecular Formula C20H20ClF2N3O3S
Molecular Weight 455.906
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

ABT-639 is a T-type calcium (Cav3.2) channel antagonist that was in development with AbbVie for the treatment for pain. ABT-639 is a potent and selective T-type calcium channel blocker. ABT-639 effectively reduces nociceptive and neuropathic pain in rats. ABT-639 produces robust antinociceptive activity in experimental pain models at doses that do not significantly alter psychomotor or hemodynamic function in the rat. ABT-639 blocks recombinant human T-type (Cav3.2) Ca2+ channels in a voltage-dependent fashion (IC50=2 uM) and attenuates low voltage-activated (LVA) currents in rat DRG neurons (IC50=8 uM). ABT-639 was significantly less active at other Ca²⁺ channels (e.g. Ca(v)1.2 and Ca(v)2.2) (IC₅₀ > 30 uM). ABT-639 has high oral bioavailability (%F = 73), low protein binding (88.9%) and a low brain:plasma ratio (0.05:1) in rodents.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.3 µM [IC50]
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Healthy adult males (aged 21 to 55 years) were randomly assigned to receive single oral doses of ABT-639, pregabalin, and placebo. A single 100-mg dose of ABT-639 had no effect on experimental pain induced by intradermal capsaicin injection.
Route of Administration: Oral
ABT-639 blocks recombinant human T-type (Cav3.2) Ca2+ channels in a voltage-dependent fashion (IC50=2 uM) and attenuates low voltage-activated (LVA) currents in rat DRG neurons (IC50=8 uM). ABT-639 is significantly less active at other Ca2+ channels (e.g. Cav1.2 and Cav2.2) (IC50>30 uM).
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:09:12 GMT 2023
Edited
by admin
on Sat Dec 16 08:09:12 GMT 2023
Record UNII
0G7D0CQ88I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ABT-639
Common Name English
ABT-639 FREE BASE
Common Name English
BENZENESULFONAMIDE, 4-CHLORO-2-FLUORO-N-(2-FLUOROPHENYL)-5-(((8AR)-HEXAHYDROPYRROLO(1,2-A)PYRAZIN-2(1H)-YL)CARBONYL)-
Systematic Name English
Code System Code Type Description
FDA UNII
0G7D0CQ88I
Created by admin on Sat Dec 16 08:09:12 GMT 2023 , Edited by admin on Sat Dec 16 08:09:12 GMT 2023
PRIMARY
CAS
1235560-28-7
Created by admin on Sat Dec 16 08:09:12 GMT 2023 , Edited by admin on Sat Dec 16 08:09:12 GMT 2023
PRIMARY
SMS_ID
300000041421
Created by admin on Sat Dec 16 08:09:12 GMT 2023 , Edited by admin on Sat Dec 16 08:09:12 GMT 2023
PRIMARY
DRUG BANK
DB15055
Created by admin on Sat Dec 16 08:09:12 GMT 2023 , Edited by admin on Sat Dec 16 08:09:12 GMT 2023
PRIMARY
PUBCHEM
46851313
Created by admin on Sat Dec 16 08:09:12 GMT 2023 , Edited by admin on Sat Dec 16 08:09:12 GMT 2023
PRIMARY
NCI_THESAURUS
C118315
Created by admin on Sat Dec 16 08:09:12 GMT 2023 , Edited by admin on Sat Dec 16 08:09:12 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY